Small Cell Lung Cancer – Ariceum SAX101
Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.
This study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing (SSTR2+) extensive-stage small cell lung cancer (ES-SCLC) and recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
Key Inclusion Criteria:
- Signed Informed Consent Form and willing to comply with all study procedures.
- Participants with ES-SCLC (defined as Stage IV per NCCN guidelines Version 1.2024) or recurrent locally advanced or metastatic MCC (per NCCN guidelines Version 1.2024) documented by histology or cytology.
- Participants eligible to receive immune checkpoint inhibitor (CPI) monotherapy at the start of treatment with 225Ac-SSO110 or patients already on CPI monotherapy for 7 weeks.
- ECOG performance status of 0 or 1. Life expectancy of at least 6 months.
- Positive 68Ga-SSO120 scan (Investigator-assessed) during screening.
- Other criteria may apply
Complete the form and our team will reach out soon to help determine your eligibility.
